AVBP
ArriVent BioPharma, Inc.
30.10$
-0.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.4% | +101.0% | -5.8% | -5.2% | -6.1% | -21.6% | +25.1% | +21.2% | +2.0% | +4.8% | +13.0% | |
| – | -11.1% | +104.7% | -5.8% | -5.2% | -22.4% | -18.1% | +34.6% | +28.4% | +3.6% | +4.7% | +13.0% | |
| – | +6.4% | +111.0% | -5.9% | -5.3% | -73.7% | -32.9% | +126.1% | -0.1% | -59.6% | +36.4% | +149.1% | |
| – | -9.6% | +111.0% | -5.9% | -5.3% | -22.6% | -19.5% | +33.9% | +27.4% | +4.2% | +4.3% | +14.3% | |
| – | -30.1% | +15.0% | -14.3% | -33.3% | +0.0% | +1.0% | +0.0% | +0.0% | -88.1% | – | – | |
| – | +16.8% | -14.3% | +20.6% | +24.8% | +13.6% | -25.1% | +51.6% | +9.8% | +20.3% | -2.4% | +10.1% | |
| – | +15.1% | -14.2% | +21.3% | +25.3% | +13.9% | -25.0% | +51.6% | +9.8% | +20.3% | -3.7% | +11.4% | |
| – | +218.2% | +5.0% | +3.4% | +95.4% | -45.5% | -14.8% | -29.0% | -42.9% | -75.0% | +607.1% | +221.2% | |
| – | -5.9% | -9.6% | -7.0% | +21.9% | -18.6% | +15.4% | -7.0% | +46.1% | +0.0% | +47.1% | -74.6% | |
| – | -12.0% | +110.0% | -6.6% | -6.5% | -7.1% | -21.4% | +23.4% | +22.1% | +0.7% | +5.5% | +13.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.2% | +0.0% | +0.9% | +3.3% | +19.7% | -8.2% | +17.2% | +5.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.